Accredited Hospitals Fail to Disclose Costs of Common Cancer Surgeries
Roughly half of hospitals accredited by the ACS-CoC failed to disclose the cost of 5 common cancer surgeries, researchers found.
Prostate Cancer
Medicine vs Food: The Patient Care Dilemma of Financial Toxicity
Physicians are calling on colleagues to bring up the cost of care and its potential impact when discussing treatment options with patients.
Metastasis-Directed Therapy Alone May Treat Solitary Prostate Cancer Recurrence
This is the first study to assess the role of metastasis-directed therapy in solitary metastatic oligorecurrent prostate cancer in the absence of systemic therapy.
18F-NaF PET-CT More Accurate Than 99mTc-MDP SPECT for Detecting Bone Metastasis
Results of a phase 3 trial suggest 18F-NaF PET-CT is more effective than 99mTc-MDP SPECT for detecting bone metastasis in patients with breast or prostate cancer.
YouTube, TikTok Videos Don’t Provide Quality Information on Prostate Cancer Screening
None of the YouTube or TikTok videos analyzed contained both high-quality and accurate information on prostate cancer screening.
Overall Cancer Mortality 18% Higher in American Indians/Alaska Natives
Breast and prostate cancer mortality rates were higher in AIAN individuals than in White individuals, despite lower incidence rates.
Long-Term Data Support HFRT as Standard Care in High-Risk Prostate Cancer
Hypofractionated radiotherapy produces similar long-term outcomes as conventionally fractionated radiotherapy in high-risk prostate cancer, a phase 3 study suggests.
Radiotherapy of Asymptomatic Bone Metastases Reduces Skeletal-Related Events
Prophylactic radiotherapy of asymptomatic bone metastases can reduce skeletal-related events and improve survival in patients with solid tumors, a study suggests.
Most Doctors Surveyed Said Life Expectancy Should Guide Cancer Screening
About 75% of physicians surveyed agreed that a life expectancy of fewer than 10 years is a reasonable criterion for stopping cancer screening.
Concurrent/Adjuvant ADT “Should Be Standard” With PORT for Localized Prostate Cancer
Concurrent/adjuvant ADT was associated with improved metastasis-free survival, distant metastasis, prostate cancer-specific mortality, and overall survival.
- Loading...
Loading...
Next post in Prostate Cancer
Loading... 
Loading...